Purposed-Built For ADC Development

Antibody-drug conjugates (ADCs) are revolutionizing cancer therapy, combining precise antibody targeting with potent payloads to deliver meaningful patient benefits. For biotech sponsors, early-phase development is critical, presenting the greatest challenges while shaping long-term program success.

Catalyst Oncology is a specialty CRO focused on guiding emerging biotechs through early-phase development to late-stage milestones. With over 20 years of experience supporting small- to mid-sized sponsors, Catalyst combines scientific expertise, operational agility, and a people-first approach. Our flexible, data-driven infrastructure enables real-time trial monitoring, while strong investigator and key opinion leader (KOL) relationships and advanced technologies ensure efficient, high-quality execution.

By integrating deep oncology knowledge with practical trial management, Catalyst Oncology empowers sponsors to navigate complex development pathways, accelerate timelines, and maximize the potential of their ADC programs — helping bring innovative therapies to patients faster.